In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone)

Clinical Cancer Research

Volumn 12, Issue 9, 2006, Pages 2912-2918

  Barker, Christopher A ^a   Burgan, William E ^a   Carter, Donna J ^a   Cerna, David ^a   Gius, David ^a   Hollingshead, Melinda G ^a   Camphausen, Kevin ^a   Tofilon, Philip J ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Radiation Research Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; DRUG VEHICLE; IRON CHELATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; IN VIVO STUDY; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIOSENSITIZATION; TUMOR CELL; TUMOR XENOGRAFT;

CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; GLIOMA; HUMANS; MALE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PYRIDINES; RADIATION-SENSITIZING AGENTS; RIBONUCLEOTIDE REDUCTASES; THIOSEMICARBAZONES;

EID: 33646734458     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2860     Document Type: Article

References (31)

1. Reichard P, Ehrenberg A. Ribonucleotide reductase - a radical enzyme. Science 1983;221:514-9.
2. Tanaka H, Arakawa H, Yamaguchi T, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000; 404:42-9.
3. Guittet O, Hakansson P, Voevodskaya N, et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 2001; 276:40647-51.
4. Kuo ML, Hwang HS, Sosnay PR, Kunugi KA, Kinsella TJ. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity. Cancer J 2003;9:277-85.
5. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992;19:1-10.
6. Sinclair WK. The Combined Effect of Hydroxyurea at X-rays on Chinese Hamster Cells in vitro. Cancer Res 1968;28:198-206.
7. Kuo ML, Kunugi KA, Lindstrom MJ, Kinsella TJ. The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells. Cancer Res 1995;55:2800-5.
8. Piver MS, Howes AE, Suit HD, Marshall N. Effect of hydroxyurea on the radiation response of C3H mouse mammary tumors. Cancer 1972;29:407-12.
9. Leyden D, Ahmed N, Hassan HT. Hydroxyurea and trimidox enhance the radiation effect in human pancreatic adenocarcinoma cells. Anticancer Res 2000;20: 133-8.
10. Symonds RP, Collingwood M, Kirwan J, et al. Concomitant hydroxyurea plus radiotherapy versus radiotherapy for carcinoma of the uterine cervix: a systematic review. Cancer Treat Rev 2004;30:405-14.
11. Shao J, Zhou B, Zhu L, et al. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 2004;64:1-6.
12. Chaston TB, Lovejoy DB, Watts RN, Richardson DR. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of Triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Clin Cancer Res 2003;9: 402-14.
13. Finch RA, Liu MC, Cory AH, Cory JG, Sartorelli AC. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): an inhibitor of ribonucleotide reductase with antineoplastic activity. Adv Enzyme Regul 1999;39:3-12.
14. O'Brien MC, Healy SF, Jr., Raney SR, et al. Discrimination of late apoptotic/necrotic cells (type III) by flow cytometry in solid tumors. Cytometry 1997;28:81-9.
15. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O'Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res 2001;61:2207-11.
16. Mason KA, Hunter NR, Raju U, et al. Flavopiridol increases therapeutic ratio of radiotherapy by preferentially enhancing tumor radioresponse. Int J Radiat Oncol Biol Phys 2004;59:1181-9.
17. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
18. Finch RA, Liu MC, Grill SP, et al. Triapine (3-amino-pyridine-2- carboxaldehyde thiosemicarbazone; 3-AP): A Potent Inhibitor of Ribonucleotide Reductase Activity wit Broad Spectrum Antitumor Activity. Biochem Pharmacol 2000;59:983-91.
19. Beckloff GL, Lerner HJ, Frost D, Russo-Alesi FM, Gitomer S. Hydroxyurea (NSC-32065) in biologic fluids: dose-concentration relationship. Cancer Chemother Rep 1965;48:57-8.
20. Moore EC, Hurlbert RB. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). Pharmacol Ther 1985;27:167-96.
21. Cory JG, Cory AH, Rappa G, et al. Inhibitors of ribonucleotide reductase. Comparative effects of amino-and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem Pharmacol 1994;48: 335-44.
22. Yen Y, Margolin K, Doroshow J, et al. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol 2004;54:331-42.
23. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J Clin Oncol 2004;22:1553-63.
24. Murren J, Modiano M, Clairmont C, et al. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors. Clin Cancer Res 2003;9:4092-100.
25. Giles FJ, Fracasso PM, Kantarjian HM, et al. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res 2003;27:1077-83.
26. Feun L, Modiano M, Lee K, et al. Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule. Cancer Chemother Pharmacol 2002;50:223-9.
27. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin Cancer Res 2003;9:4227-39.
28. Sinclair WK. Hydroxyurea: differential lethal effects on cultured mammalian cells during the cell cycle. Science 1965;150:1729-31.
29. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125) IdU-induced DNA double-strand breaks with g-H2AX antibody. Radiat Res 2002;158:486-92.
30. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low X-ray doses. Proc Natl Acad Sci U S A 2003; 100:5057-62.
31. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003;23: 5706-15.